BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BillionToOne, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$101.03+2.91 (+2.97%)
Close on Oct 19, 2026
- Market cap
- $5.50B
- P/E (TTM)
- 721.6
- Dividend yield
- –
BillionToOne, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Prenatal | $94.25M | $96.53M | $86.10M | $74.07M | $60.85M | $56.08M | $43.22M | $36.60M | 86.1% | +54.9% |
| Oncology | $13.66M | $10.72M | $9.14M | $8.69M | $4.95M | $2.18M | $1.09M | $1.14M | 12.5% | +176.2% |
| Clinical trial support and other services | $1.54M | $1.14M | $810.00K | $761.00K | $774.00K | $710.00K | $763.00K | $680.00K | 1.4% | +98.6% |
By region
From the segment and revenue-disaggregation notes of BillionToOne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.